Welcome to our dedicated page for Concord Medical news (Ticker: CCM), a resource for investors and traders seeking the latest updates and insights on Concord Medical stock.
Concord Medical Services Holdings Limited (NYSE: CCM) is a China-based healthcare provider focused on oncology. Its public announcements describe a full cycle of premium oncology services, including cancer diagnosis, treatment, education and prevention, delivered through self-owned cancer hospitals and clinics and a network of partnered hospitals across China. The company’s news flow provides insight into how it develops and operates these oncology services.
News about Concord Medical frequently covers its progress in proton therapy and precision radiation therapy. Recent releases highlight Guangzhou Concord Cancer Hospital’s commencement of proton therapy operations, specialized treatment protocols for conditions such as nasopharyngeal carcinoma and central nervous system tumors, and pediatric oncology cases. Another subsidiary announcement reports completion of what it describes as China’s first proton therapy for choroidal malignant melanoma at Guangzhou Concord Cancer Center, using pencil beam scanning proton therapy with real-time guidance.
Investors and observers can also find updates on regulatory and licensing milestones, such as the granting of a large medical equipment procurement license for proton equipment and the approval of a Registration Certificate for Medical Device for proton therapy equipment related to the company’s operations. These items help explain the timing and scope of Concord Medical’s proton therapy services.
In addition, Concord Medical’s news includes interim financial results, details of its annual and special shareholder meetings, changes in governance, and developments at its listed subsidiary Concord Healthcare Group Co., Ltd. on the Hong Kong Stock Exchange. For users following CCM, this news page brings together earnings releases, clinical and technology updates, regulatory announcements and corporate actions that shape the company’s oncology-focused business over time.
Concord Medical Services Holdings (NYSE: CCM), a Chinese healthcare provider specializing in cancer treatment, research, education, and prevention, has regained compliance with the New York Stock Exchange's (NYSE) minimum price requirement. The company received a Compliance Notice on August 6, 2024, confirming that it is no longer below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period.
This development follows a previous notification from the NYSE on February 12, 2024, which had informed Concord Medical that it was below compliance standards due to the trading price of its American Depositary Shares. With this latest update, Concord Medical has successfully addressed the compliance issue and is no longer considered below the NYSE Minimum Price Requirement.
Concord Medical (NYSE: CCM) announced plans to change the ADS Ratio of its American depositary shares (ADS) from 1 ADS representing 3 Class A ordinary shares to 1 ADS representing 30 Class A ordinary shares. This change is expected to be effective on July 30, 2024. The ADS holders must surrender and exchange every 10 existing ADSs for 1 new ADS. JPMorgan Chase Bank will manage the exchange process. No fractional new ADSs will be issued; fractional entitlements will be sold, and proceeds will be distributed to ADS holders. This ratio change is anticipated to proportionally increase the ADS trading price, but cannot guarantee it will be ten times the previous trading price.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Concord Medical Services Holdings Limited (NYSE: CCM) announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2022. This report is accessible on both Concord Medical's investor relations website and the SEC's website. Concord Medical specializes in oncology services, providing a full cycle of cancer diagnosis, treatment, education, and prevention via a network of radiotherapy and diagnostic imaging centers in China. The company emphasizes the deployment of advanced technology, including proton therapy systems, to enhance cancer care quality and accessibility. Shareholders can request a hard copy of the report free of charge.
Concord Medical Services Holdings Limited (NYSE: CCM) will hold its 2022 annual general meeting of shareholders on December 30, 2022, at 10:00 a.m. Beijing Time. The meeting will take place at the Global Trade Center in Beijing, and the shareholder record date is November 30, 2022. No proposals will be submitted for approval, as the meeting aims to facilitate discussions between shareholders and management. Additionally, the Company’s annual report on Form 20-F for the fiscal year ending December 31, 2021, is accessible on its investor relations website.
Concord Medical Services Holdings Limited (NYSE: CCM) successfully hosted the Second Annual Academic Meeting with MD Anderson Cancer Center on November 11-12, 2022. The event focused on 'Immuno-Oncology: Confronting the Whole Cancer Continuum,' gathering experts from China and the U.S. to discuss advancements in cancer treatment and research. Notable topics included immunotherapy for cancer prevention and emerging cellular therapies. The meeting attracted nearly 100 oncology scholars globally and demonstrated Concord Medical's commitment to enhancing international collaboration in oncology.
FAQ
What is the current stock price of Concord Medical (CCM)?
What is the market cap of Concord Medical (CCM)?
